Table 2.
Survival Outcomes by Patient Characteristics
| Characteristic | Level | OS
|
||
|---|---|---|---|---|
| Deaths / Total | 1-yr (SE) | P-value | ||
| All Patients | 45 / 64 | 71%(6%) | ||
|
| ||||
| Univariate | ||||
|
| ||||
| Age* | 0.45 | |||
| <60 | 23 / 37 | 75%(7%) | ||
| >=60 | 22 / 27 | 65%(9%) | ||
|
| ||||
| Chemotherapy Duration* | 0.15 | |||
| <4 | 29 / 38 | 68%(8%) | ||
| ≥4 | 16 / 26 | 74%(9%) | ||
|
| ||||
| Log(SUV Uptake of Primary At Baseline)* | 0.76 | |||
| <2.61 | 17 / 22 | 72%(10%) | ||
| ≥2.61 | 19 / 24 | 62%(10%) | ||
|
| ||||
| Log(SUV Uptake of Primary After Chemotherapy)* | 0.30 | |||
| <1.74 | 10 / 19 | 78%(10%) | ||
| ≥1.74 | 16 / 19 | 62%(11%) | ||
|
| ||||
| Gender | 0.20 | |||
| Male | 38 / 52 | 66%(7%) | ||
| Female | 7 / 12 | 92%(8%) | ||
|
| ||||
| Histology Grade | 0.76 | |||
| G2 Moderately differentiated | 17 / 24 | 62%(10%) | ||
| G3 Poorly differentiated | 28 / 40 | 77%(7%) | ||
|
| ||||
| ECOG PS | 0.83 | |||
| 0 | 13 / 20 | 70%(10%) | ||
| ≥1 | 31 / 42 | 70%(7%) | ||
|
| ||||
| Location of Tumor | 0.11 | |||
| Esophagus/AEG 1/AEG 2 | 28 / 37 | 62%(8%) | ||
| Gastric/AEG 3 | 17 / 27 | 85%(7%) | ||
|
| ||||
| Distribution of Distant Metastases | 0.86 | |||
| Cytology | 9 / 13 | 68%(13%) | ||
| Distant lymph node | 24 / 33 | 72%(8%) | ||
| Peritoneum/Peritoneum+ Distant lymph node | 7 / 10 | 70%(14%) | ||
| Visceral | 5 / 8 | 71%(17%) | ||
|
| ||||
| Adenocarcinoma Subgroup | 0.40 | |||
| SRC/M &SRC | 9 / 12 | 64%(14%) | ||
| NE/NOS | 36 / 52 | 73%(6%) | ||
|
| ||||
| Type of Consolidation | 0.08 | |||
| 40–50 | 11 / 21 | 90%(7%) | ||
| >50 | 33 / 42 | 62%(7%) | ||
|
| ||||
| Surgery** | 0.03 | |||
| Yes | 8 / 14 | 92%(7%) | ||
| No | 37 / 64 | 67%(7%) | ||
OS=Overall Survival; SE=Standard Error; SUV=Standardized Uptake Value; ECOG PS= Eastern Cooperative Oncology Group Performance Score; AEG=Adenocarcinoma of Esophagogastric Junction; SRC=Signet Ring Carcinoma; M= Mucinous; NE= Neuro Endocrine; NOS=Not Otherwise Specified.
P-values were calculated based on continuous values for age at presentation at MDACC, duration of all chemo, and logarithm of SUV uptake of primary at baseline and after chemotherapy, and excluded patients with missing values for that characteristic.
Time varying covariate. All patients begin in the “No” group. Patients who receive surgery are censored in the “No” group on the date of surgery. Then they start in the “Yes” group on that date. 1-year OS for “Yes” patients is the time since surgery.